We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 4

1.
FIGURE 1

FIGURE 1. SPARC is variably expressed by platinum resistant ovarian cancer cells in vitro. From: Secreted protein acidic and rich in cysteine as a regulator of murine ovarian cancer growth and chemosensitivity.

A, Cell lysates and B, corresponding conditioned media from the indicated cell lines were evaluated for SPARC expression by Western blot analysis. β-Actin was used as a loading control.

Shawna L. Bull Phelps, et al. Am J Obstet Gynecol. ;200(2):180.e1-180.e7.
2.
FIGURE 4

FIGURE 4. Cisplatin improves survival in tumor-bearing SP−/− mice. From: Secreted protein acidic and rich in cysteine as a regulator of murine ovarian cancer growth and chemosensitivity.

OSEID8 cells (5 × 106) were injected intraperitoneally into WT and SP−/− mice (n = 12/genotype). Starting on day 41 after tumor cell injection, the mice were treated weekly for 4 weeks with either vehicle (n = 6/genotype) or cisplatin (5 mg/kg, n = 6/genotype). Mice were monitored daily for signs of morbidity and disease. A–C, Kaplan-Meier survival curves for each genotype are shown. A, Cisplatin improved survival significantly (P = .0048) in SP−/− mice but not B, WT mice. C, In the absence of therapy, survival of SP−/− mice was diminished significantly (P = .0005) compared with WT controls.

Shawna L. Bull Phelps, et al. Am J Obstet Gynecol. ;200(2):180.e1-180.e7.
3.
FIGURE 2

FIGURE 2. Forced expression of tumor-associated SPARC reduces cell proliferation. From: Secreted protein acidic and rich in cysteine as a regulator of murine ovarian cancer growth and chemosensitivity.

Ovarian cancer cells were transiently transfected with SPARC (SP, open bars) or a control empty vector (EV, filled bars). A, Cell number was determined by counting at the indicated time points after transfection. Mean cell counts (Y axis) at 24, 48, and 72 hours after transfection is shown with SEM bars. B, Western blot analysis was performed on cell lysates to confirm transfection after 72 hours. HCC60 and SKOV3 are shown. C, Liquid culture colony formation assays were also performed on OSEID8 and ES2 to confirm a significant reduction in cell growth. Fourteen days after plating, colony counts were recorded and mean colony-forming units calculated (± SEM).

Shawna L. Bull Phelps, et al. Am J Obstet Gynecol. ;200(2):180.e1-180.e7.
4.
FIGURE 3

FIGURE 3. Tumor growth and response to cisplatin therapy. From: Secreted protein acidic and rich in cysteine as a regulator of murine ovarian cancer growth and chemosensitivity.

Tumor growth and response to cisplatin therapy is enhanced in the absence of host-derived SPARC. OSEID8 cells (5 × 106) were injected intraperitoneally into WT and SP−/− mice (n = 12/genotype). Starting on day 41 after tumor cell injection, the mice were treated weekly for 4 weeks with either vehicle (n = 6/genotype) or cisplatin (5 mg/kg, n = 6/genotype). A, The number of WT (filled bars) and SP−/− (open bars) mice showing signs of ascites at day 41 or B, the last day of assessment is shown. C, The extent of tumor burden (volume in cubic millimeters) was determined at the time the animals were killed. Mean volume ± SEM is shown. A significant decrease in tumor volume is seen in the SP−/− mice treated with cisplatin (P = .02 comparing SP−/− control and SP−/− treated mice).

Shawna L. Bull Phelps, et al. Am J Obstet Gynecol. ;200(2):180.e1-180.e7.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk